Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.45 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888431 | 0.90 | FFAR1 (0.42) | FFAR1FFAR4L3MBTL1PTGER4PTGER3 | |
| SCHEMBL36006022 | 0.90 | FFAR1 (0.42) | FFAR1FFAR4L3MBTL1PTGER4PTGER3 | |
| SCHEMBL35843152 | 0.89 | FFAR1 (0.55) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL1808327 | 0.89 | FFAR1 (0.55) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL1808817 | 0.87 | PPARG (0.48) | FFAR1FFAR4PPARDPPARGPPARA | |
| SCHEMBL1889009 | 0.87 | FFAR1 (0.54) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL17601823 | 0.87 | FFAR1 (0.51) | FFAR1FFAR4PTGER4PTGER3PPARG | |
| SCHEMBL16605158 | 0.84 | FFAR1 (0.54) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL16863784 | 0.84 | FFAR1 (0.52) | FFAR1FFAR4PTGER4PTGER3PPARG | |
| SCHEMBL16863742 | 0.84 | FFAR1 (0.48) | FFAR1FFAR4PTGER4PTGER3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | UNIVERSITAT DE VALENCIA (ES) | 2016-06-30 | — | — | US | claimed |
| EP-2496544-B1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN S L (SE) | 2014-08-20 | — | — | EP | claimed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | claimed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | claimed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | UNIVERSITAT DE VALENCIA (ES) | 2016-06-30 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | JUAN SAUS (ES) | 2016-03-24 | — | — | US | disclosed |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2014-03-20 | — | — | US | disclosed |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2014-03-20 | — | — | US | disclosed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | disclosed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | disclosed |
| WO-2011054530-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN, S.L. (ES) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885LMNA 3038/4885 |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885LMNA 3038/4885 |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885LMNA 3038/4885 |
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | VIM, EPCAM, CDH1 | FFAR1 4443/4885FFAR4 4492/4885LMNA 4406/4885 |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885LMNA 3038/4885 |
| US-20160083327-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | FFAR1 2951/4885FFAR4 2889/4885LMNA 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.